• OTS
  • January 30, 2021
SHARE
Post Views: 584

Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP. ESC Heart Fail. 2020 Dec 7.

Pubmed

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy

Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy

April 23rd, 2021
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

March 15th, 2021
Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

March 15th, 2021
The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

February 16th, 2021
Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

February 16th, 2021